IGC Pharma Past Earnings Performance
Past criteria checks 0/6
IGC Pharma's earnings have been declining at an average annual rate of -21.8%, while the Pharmaceuticals industry saw earnings growing at 9.7% annually. Revenues have been declining at an average rate of 47.7% per year.
Key information
-21.8%
Earnings growth rate
-13.8%
EPS growth rate
Pharmaceuticals Industry Growth | 7.3% |
Revenue growth rate | -47.7% |
Return on equity | -156.2% |
Net Margin | -1,163.2% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How IGC Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 1 | -14 | 8 | 3 |
30 Sep 23 | 1 | -11 | 8 | 3 |
30 Jun 23 | 1 | -11 | 9 | 3 |
31 Mar 23 | 1 | -12 | 9 | 3 |
31 Dec 22 | 1 | -14 | 9 | 4 |
30 Sep 22 | 1 | -14 | 10 | 4 |
30 Jun 22 | 1 | -16 | 12 | 3 |
31 Mar 22 | 0 | -15 | 12 | 2 |
31 Dec 21 | 0 | -11 | 10 | 1 |
30 Sep 21 | 0 | -11 | 11 | 1 |
30 Jun 21 | 0 | -9 | 8 | 1 |
31 Mar 21 | 1 | -9 | 8 | 1 |
31 Dec 20 | 1 | -9 | 8 | 1 |
30 Sep 20 | 1 | -8 | 7 | 1 |
30 Jun 20 | 3 | -8 | 6 | 1 |
31 Mar 20 | 4 | -7 | 6 | 1 |
31 Dec 19 | 6 | -6 | 5 | 2 |
30 Sep 19 | 6 | -5 | 5 | 1 |
30 Jun 19 | 5 | -5 | 4 | 1 |
31 Mar 19 | 5 | -4 | 4 | 1 |
31 Dec 18 | 5 | -3 | 2 | 1 |
30 Sep 18 | 4 | -2 | 2 | 0 |
30 Jun 18 | 4 | -2 | 2 | 0 |
31 Mar 18 | 2 | -2 | 2 | 0 |
31 Dec 17 | 1 | -2 | 3 | 0 |
30 Sep 17 | 1 | -2 | 2 | 0 |
30 Jun 17 | 0 | -2 | 2 | 0 |
31 Mar 17 | 1 | -2 | 2 | 0 |
31 Dec 16 | 2 | -3 | 2 | 0 |
30 Sep 16 | 3 | -3 | 3 | 0 |
30 Jun 16 | 5 | -3 | 3 | 0 |
31 Mar 16 | 6 | -3 | 3 | 0 |
31 Dec 15 | 7 | -3 | 3 | 0 |
30 Sep 15 | 9 | -4 | 3 | 0 |
30 Jun 15 | 9 | -4 | 3 | 0 |
31 Mar 15 | 8 | -5 | 4 | 0 |
31 Dec 14 | 5 | -4 | 4 | 0 |
30 Sep 14 | 3 | -4 | 3 | 0 |
30 Jun 14 | 2 | -4 | 3 | 0 |
31 Mar 14 | 2 | -3 | 2 | 0 |
31 Dec 13 | 4 | -3 | 3 | 0 |
30 Sep 13 | 8 | -3 | 3 | 0 |
30 Jun 13 | 8 | -2 | 3 | 0 |
Quality Earnings: IGS1 is currently unprofitable.
Growing Profit Margin: IGS1 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IGS1 is unprofitable, and losses have increased over the past 5 years at a rate of 21.8% per year.
Accelerating Growth: Unable to compare IGS1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IGS1 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (3%).
Return on Equity
High ROE: IGS1 has a negative Return on Equity (-156.25%), as it is currently unprofitable.